Quality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone:ax-panc-sy001: A phase II randomized study.

被引：2

作者：

Yalcin, Suayib

Dane, Faysal

Oksuzoglu, Berna

Yildirim, Nuriye

Isikdogan, Abdurrahman

Ozkan, Metin

Demirag, Guzin

Coskun, Hasan Senol

Karabulut, Bulent

Evrensel, Turkkan

Ustaoglu, Mehmet Ali

Ozdemir, Feyyaz

Turna, Hande

Yavuzsen, Tugba

Aykan, Faruk

Sevinc, Alper

Akbulut, Hakan

Yuce, Deniz

Hayran, Mutlu

Kilickap, Saadettin

机构：

[1] Hacettepe Univ, Ankara, Turkey

[2] Marmara Univ, Istanbul, Turkey

[3] Dr A Y Ankara Oncol Training & Res Hosp, Ankara, Turkey

[4] Ankara Numune Training & Res Hosp, Ankara, Turkey

[5] Dicle Univ, Med Sch, Diyarbakir, Turkey

[6] Erciyes Univ, Kayseri, Turkey

[7] Ondokuzmayis Univ Med Oncol, Samsun, Turkey

[8] Akdeniz Univ, Antalya, Turkey

[9] Ege Univ, Izmir, Turkey

[10] Uludag Univ, Pittsburgh, PA USA

[11] Lutfi Kirdar Hosp, Istanbul, Turkey

[12] Karadeniz Tech Univ, Fac Med, Trabzon, Turkey

[13] Istanbul Univ, Cerrahpasa Sch Med, Istanbul, Turkey

[14] Dokuz Eylul Univ, Oncol Inst, Izmir, Turkey

[15] Istanbul Univ, Inst Oncol, Istanbul, Turkey

[16] Gaziantep Univ, Gaziantep, Turkey

[17] Hacettepe Univ, Canc Inst, Ankara, Turkey

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期

关键词：

D O I：

10.1200/JCO.2018.36.4_suppl.346

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

346

引用

页数：1

共 50 条

[1] Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine plus nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study
Yalcin, Suayib
Dane, Faysal
Oksuzoglu, Berna
Ozdemir, Nuriye Yildirim
Isikdogan, Abdurrahman
Ozkan, Metin
Demirag, Guzin Gonullu
Coskun, Hasan Senol
Karabulut, Bulent
Evrensel, Turkkan
Ustaoglu, Mehmet Ali
Ozdemir, Feyyaz
Turna, Hande
Yavuzsen, Tugba
Aykan, Faruk
Sevinc, Alper
Akbulut, Hakan
Yuce, Deniz
Hayran, Mutlu
Kilickap, Saadettin
BMC CANCER, 2020, 20 (01)
[2] Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study
Suayib Yalcin
Faysal Dane
Berna Oksuzoglu
Nuriye Yildirim Ozdemir
Abdurrahman Isikdogan
Metin Ozkan
Guzin Gonullu Demirag
Hasan Senol Coskun
Bulent Karabulut
Turkkan Evrensel
Mehmet Ali Ustaoglu
Feyyaz Ozdemir
Hande Turna
Tugba Yavuzsen
Faruk Aykan
Alper Sevinc
Hakan Akbulut
Deniz Yuce
Mutlu Hayran
Saadettin Kilickap
BMC Cancer, 20
[3] Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial
Cascinu, Stefano
Berardi, Rossana
Bianco, Roberto
Bilancia, Domenico
Zaniboni, Alberto
Ferrari, Daris
Mosconi, Stefania
Spallanzani, Andrea
Cavanna, Luigi
Leo, Silvana
Negri, Francesca
Beretta, Giordano D.
Sobrero, Alberto
Banzi, Maria
Morabito, Alberto
Bittoni, Alessandro
Marciano, Roberta
Ferrara, Domenica
Noventa, Silvia
Piccirillo, Maria C.
Labianca, Roberto
Mosconi, Cristina
Gardini, Andrea Casadei
Gallo, Ciro
Perrone, Francesco
EUROPEAN JOURNAL OF CANCER, 2021, 148 : 422 - 429
[4] Phase I study of nab-paclitaxel and gemcitabine combination in patients with advanced pancreatic cancer
Drengler, R. L.
Smith, L. S.
Wood, T. E.
Borad, M. J.
Ramanathan, R. K.
Laheru, D. A.
Hidalgo, M.
Von Hoff, D. D.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[5] A phase II study of nab-paclitaxel and gemcitabine in Korean patients with metastatic pancreatic cancer
Lee, S. J.
Oh, D-Y.
Kang, J-H.
Choi, H. J.
Lee, M. A.
Oh, S. Y.
Kim, S-T.
Park, Y. S.
Ryu, B-Y.
Park, J. O.
ANNALS OF ONCOLOGY, 2018, 29
[6] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Chen, Shuling
Li, Jiaxin
Dong, Aoran
Liu, Zelong
Zhu, Meiyan
Jin, Meng
Wei, Guangyan
Wu, Shuang
Wang, Yan
Chen, Yong
Peng, Zhenwei
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
[7] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Shuling Chen
Jiaxin Li
Aoran Dong
Zelong Liu
Meiyan Zhu
Meng Jin
Guangyan Wei
Shuang Wu
Yan Wang
Yong Chen
Zhenwei Peng
Journal of Hematology & Oncology, 16
[8] Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer
Suguru Yamada
Tsutomu Fujii
Yukihiro Yokoyama
Hiroki Kawashima
Osamu Maeda
Kojiro Suzuki
Tohru Okada
Eizaburo Ono
Junpei Yamaguchi
Nao Takano
Hideki Takami
Masamichi Hayashi
Yukiko Niwa
Yoshiki Hirooka
Yoshiyuki Ito
Shinji Naganawa
Yuichi Ando
Masato Nagino
Hidemi Goto
Yasuhiro Kodera
Cancer Chemotherapy and Pharmacology, 2018, 81 : 815 - 821
[9] Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer
Yamada, Suguru
Fujii, Tsutomu
Yokoyama, Yukihiro
Kawashima, Hiroki
Maeda, Osamu
Suzuki, Kojiro
Okada, Tohru
Ono, Eizaburo
Yamaguchi, Junpei
Takano, Nao
Takami, Hideki
Hayashi, Masamichi
Niwa, Yukiko
Hirooka, Yoshiki
Ito, Yoshiyuki
Naganawa, Shinji
Ando, Yuichi
Nagino, Masato
Goto, Hidemi
Kodera, Yasuhiro
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (05) : 815 - 821
[10] A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.
Shan, Yan-Shen
Li, Chung-Pin
Khan, Gazala
Lee, Woo Jin
Choi, Hye Jin
Chang, Heung-Moon
Lee, Moon Hee
Wallmark, John M.
Chen, Pei-Ni
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 648 - 648

← 1 2 3 4 5 →